Table 1. Selected trials of targeted therapy in advanced thymic epithelial tumors.
| Intervention | Target | N | Responses [%] | TTP/PFS (months) | OS (months) | Reference |
|---|---|---|---|---|---|---|
| Gefitinib | EGFR | 26 | 1 [4] | 4 | Not reported | (63) |
| Imatinib | KIT | 15 | 0 | 3 | Not reached | (64) |
| Belinostat | HDAC | 40 | 2 [5] | 5.8 | 19.2 | (65) |
| Cixutumumab | IGF-1R | 49 | 5 [10] | 8.2 | 16.2 | (66) |
| Saracatinib | SRC | 21 | 0 | 5.3 | 23.1 | (67) |
| Buparlisib* | PI3K | 14 | 1 [7] | 11.1 | 22.5 | (68) |
| Everolimus | mTOR | 51 | 6 [12] | 10.1 | 25.7 | (12) |
| Sunitinib** | KIT, VEGF, PDGFR | 23 | 6 [26] | 7.2 | Not reached | (11) |
*, thymoma only; **, thymic carcinoma only. N, number of evaluable subjects; TTP, time-to-progression; PFS, progression-free survival; OS, overall survival.